New insights into evaluating effective t-cell responses to HIV

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Allen, T M ^a   Watkins, D I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

HIV, SIV, CTL, T helper

Indexed keywords

CD8 ANTIGEN; CYTOKINE;

ANALYTIC METHOD; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE FUNCTION; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAINING; T LYMPHOCYTE SUBPOPULATION; VIRUS GENOME;

EID: 0035666792     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00015     Document Type: Review

References (100)

1. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques
2. Shutting down HIV
3. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
4. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques
5. + lymphocyte response in acutely infected rhesus monkeys
6. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
7. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques
8. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes
9. Immune control of HIV-1 after early treatment of acute infection
10. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
11. Phenotypic analysis of antigen-specific T lymphocytes
12. ELISPOT assay to detect cytokine-secreting murine and human cells
13. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
14. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
15. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors
16. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
17. Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
18. Rapid and comprehensive characterization of HIV-1-specific CTL responses using a peptide-matrix-system spanning all expressed HIV-1 proteins
19. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
20. Functional impairment of simian immunodeficiency virus-specific CD8(+) T cells during the chronic phase of infection
21. Acute CTL escape (ACES) vaccination: An alternate approach to HIV vaccine development
22. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
23. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children
24. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon
25. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1
26. Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease
27. Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: Comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy
28. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection
29. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
30. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles
31. Human memory CTL response specific for influenza A virus is broad and multispecific
32. SIV SHIV CTL epitopes identified in macaques
33. Recent advances in HIV-1 CTL epitope characterization
34. CD8+ lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule Mamu-A*01: Implications for vaccine design and testing
35. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infections
36. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
37. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
38. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
39. Vaccination with Rev and Tat against AIDS
40. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
41. HIV vaccines some lessons learned from nonhuman primate models
42. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
43. Vpr is preferentially targeted by CTL during HIV-1 infection
44. Evolutionary and immunolgical implications of contemporary HIV-1 variation
45. Virus-specific CTL responses select for amino acid variation in SIV Env and Nef
46. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses
47. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS
48. Identification of multiple HIV-1 CTL epitopes presented by HLA-B*5101 molecules
49. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
50. Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast
51. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
52. Definition of specific peptide motifs for four major HLA-A alleles
53. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage
54. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro
55. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: Evidence for HLA class I-restricted triggering of cytolytic and non-cytolytic mechanisms
56. Antiviral pressure exerted By HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
57. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
58. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
59. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition
60. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
61. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope
62. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection
63. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
64. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avitity CTL
65. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
66. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection
67. Expression of the mucosal homing receptor alpha4beta7 correlates with the ability of CD8+ memory T cells to clear rotavirus infection
68. Characterization of HIV-1-specific cytotoxic T lymphocytes expressing the mucosal lymphocyte integrin CD103 in rectal and duodenal lymphoid tissue of HIV-1-infected subjects
69. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa
70. Identification of SIV env-specific CTL in the jejunal mucosa in vaginally exposed, seronegative rhesus macaques (Macaca mulatta)
71. Induction of AIDS virus-specific CTL activity in fresh, unstimulated PBL from rhesus macaques vaccinated with a DNA prime/MVA boost regimen
72. Effective induction of SIV-specific CTL in macaques using a DNA prime-MVA boost vaccination regimen
73. Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus
74. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
75. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
76. T4+ T helper cell function in vlvo: Differential requirement for induction of antiviral cytotoxic T-cell and antibody responses
77. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
78. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
79. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge
80. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro
81. Changing virus-host interactions in the course of HIV-1 infection
82. Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection
83. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals
84. Pathogenesis of human immunodeficiency virus infection
85. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection
86. HIV-specific CD4+ T cells are maintained in untreated patients with or without proliferative responses to HIV antigens
87. Identification of highly attenuated mutants of simian immunodeficiency virus
88. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production
89. Characterization of SIV-specific CD4+ T-helper proliferative responses in macaques immunized with live-attenuated SIV
90. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
91. HIV type 1-specific helper T cells: A critical host defense
92. Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer
93. Human immunodeficiency virus type 1- and cytomegalovirus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells
94. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance
95. Control of SIV rebound through structured treatment interruptions during early infection
96. Less is more? STI in acute and chronic HIV-1 infection
97. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection
98. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection
99. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
100. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination